Nestle divests peanut allergy business Palforzia By Reuters

0
231
Nestle divests peanut allergy business Palforzia By Reuters


© Reuters. FILE PHOTO: Capsules of Palforzia are shown containing pharmaceutical grade peanut powder, for use in oral immunotherapy among patients with peanut allergies, manufactured by Aimmune Therapeutics, based in Brisbane, California, in this handout obtained by

ZURICH (Reuters) – Nestle has divested its peanut allergy treatment business Palforzia, the Swiss food company said on Monday, following its strategic review of the division.

Nestle said it has offloaded Palforzia to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies.

Nestle will receive milestone payments and ongoing royalties from Stallergenes Greer, it said.



Source link